Epigenetix is a clinical stage pharma company with a first-in-class oral cancer drug about to begin phase on trials at 5 leading US cancer centers. We will include patients with prostate cancer,  pancreatic cancer, breast cancer, sarcoma, NUT carcinoma and other cancers where our drug has shown
unprecedented anti-cancer activity. Our drug was selected among many
other drug candidates to potently inhibit three different validated
cancer drug targets:  p300/CBP + BRD4+ CECR2. Treatment
results in elimination of both the tumor itself as well as associated metastases. This powerful drug fights cancer in multiple ways: (1) by eradicating tumor cells directly (cytotoxic therapy), (2) by unleashing the body’s immune system (immunotherapy), and (3) by inhibiting cancer-inducing male and female hormone actions (hormone therapy). While presently pursued as monotherapy, synergy with checkpoint inhibitors, PARP inhibitors, CDK4/6 inhibitors as well as epigenetic drugs, such as EZH2 inhibitors ,has been shown preclinically.

Epigenetix

Org chart

Teams

Offices